Analysts Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $9.33

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) has received a consensus rating of "Buy" from the four ratings firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $7.40.

Separately, HC Wainwright reissued a "buy" rating and issued a $3.00 price target (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

Hedge Funds Weigh In On Caribou Biosciences

A number of large investors have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. raised its position in Caribou Biosciences by 19.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,442,121 shares of the company's stock worth $1,317,000 after purchasing an additional 234,052 shares during the period. AQR Capital Management LLC increased its position in shares of Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company's stock valued at $480,000 after acquiring an additional 463,391 shares during the period. Pale Fire Capital SE increased its position in shares of Caribou Biosciences by 7.2% in the first quarter. Pale Fire Capital SE now owns 786,722 shares of the company's stock valued at $718,000 after acquiring an additional 52,518 shares during the period. Aberdeen Group plc increased its position in shares of Caribou Biosciences by 126.5% in the first quarter. Aberdeen Group plc now owns 411,144 shares of the company's stock valued at $375,000 after acquiring an additional 229,657 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Caribou Biosciences in the first quarter valued at about $302,000. Hedge funds and other institutional investors own 77.51% of the company's stock.

Caribou Biosciences Stock Up 4.4%

CRBU traded up $0.04 on Monday, hitting $0.88. The company's stock had a trading volume of 522,394 shares, compared to its average volume of 1,516,902. The company's 50 day simple moving average is $0.86 and its 200-day simple moving average is $1.43. The firm has a market cap of $81.57 million, a P/E ratio of -0.53 and a beta of 2.36. Caribou Biosciences has a 12 month low of $0.66 and a 12 month high of $3.72.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. Equities analysts predict that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.